- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05396638
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
January 29, 2024 updated by: University of Colorado, Denver
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents
This project seeks to learn more about the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents to address a fundamental gap in knowledge and identify biomarkers that may help distinguish youth who relapse from youth who remain sober.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Learning the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents addresses a fundamental gap in knowledge and may identify biomarkers that help distinguish youth who relapse from youth who remain sober.
The specific aims of the project are to:
- Measure endocannabinoid (eCB) and endogenous opioid (endorphin) levels in the blood of adolescents who use cannabis regularly and adolescents who never use cannabis. We expect eCB and endorphin levels to differ significantly in adolescents who use cannabis regularly compared to adolescents who do not.
- Characterize circulating eCB and endorphin levels at baseline, during abstinence, and after natural resumption of cannabis use.
- Collect data to evaluate cannabis craving and to test for association of craving with eCB and endorphin levels in adolescents who use cannabis regularly. We expect that larger changes in eCB and endorphin levels will be associated with higher craving scores.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jesse Hinckley, MD, PhD
- Phone Number: 303-724-3090
- Email: jesse.hinckley@cuanschutz.edu
Study Contact Backup
- Name: Kristen Raymond, BA
- Phone Number: 303-724-3196
- Email: kristen.raymond@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Anschutz Medical Campus
-
Contact:
- Jesse Hinckley, MD, PhD
- Phone Number: 303-724-5690
- Email: jesse.hinckley@cuanschutz.edu
-
Principal Investigator:
- Jesse D Hinckley, MD, PhD
-
Contact:
- Kristen Raymond, BA
- Phone Number: 303-724-3196
- Email: kristen.raymond@cuanschutz.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 25 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 14 to 25 years of age.
- Use cannabis at least twice a week for the past month.
Exclusion Criteria:
- Refusal of valid written consent,
- Current psychosis,
- Obvious intoxication,
- Current risk of suicide,
- Violence sufficiently great to interfere with evaluation or to endanger evaluators,
- Obvious intellectual deficiency as noted during the informed consent process, or inability of patient or family to comply with the study protocol.
- Use of other illicit drugs in the past 90 days by self-report or detected by urine drug test.
- Use of opioid medications for medical or recreational purposes currently or within the past 90 days.
- Does not have access to an Internet connected devise or cannot use Zoom.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Contingency Management
Abstinence will be rewarded following a contingency management (CM) payment scale.
|
Participants will be paid for abstinence at each study visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cannabinoid levels in blood
Time Frame: Collected at Baseline
|
Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35.
We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes.
|
Collected at Baseline
|
Cannabinoid levels in blood
Time Frame: Collected at Week 2
|
Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35.
We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes.
|
Collected at Week 2
|
Cannabinoid levels in blood
Time Frame: Collected at Week 4
|
Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35.
We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes.
|
Collected at Week 4
|
Cannabinoid levels in blood
Time Frame: Collected at Week 8
|
Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35.
We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes.
|
Collected at Week 8
|
Endocannabinoid levels in blood
Time Frame: Collected at Baseline
|
We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood.
|
Collected at Baseline
|
Endocannabinoid levels in blood
Time Frame: Collected at Week 2
|
We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood.
|
Collected at Week 2
|
Endocannabinoid levels in blood
Time Frame: Collected at Week 4
|
We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood.
|
Collected at Week 4
|
Endocannabinoid levels in blood
Time Frame: Collected at Week 8
|
We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood.
|
Collected at Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endorphin levels in blood
Time Frame: Collected at Baseline
|
Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
|
Collected at Baseline
|
Endorphin levels in blood
Time Frame: Collected at Week 2
|
Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
|
Collected at Week 2
|
Endorphin levels in blood
Time Frame: Collected at Week 4
|
Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
|
Collected at Week 4
|
Endorphin levels in blood
Time Frame: Collected at Week 8
|
Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
|
Collected at Week 8
|
Cannabis Craving
Time Frame: Collected at Baseline
|
Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving.
|
Collected at Baseline
|
Cannabis Craving
Time Frame: Collected at Week 2
|
Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving.
|
Collected at Week 2
|
Cannabis Craving
Time Frame: Collected at Week 4
|
Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving.
|
Collected at Week 4
|
Cannabis Craving
Time Frame: Collected at Week 8
|
Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving.
|
Collected at Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
May 16, 2022
First Submitted That Met QC Criteria
May 24, 2022
First Posted (Actual)
May 31, 2022
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-0553
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)Not yet recruitingTobacco Use | Cannabis | Cannabis Use | Vaping | THC | Cannabis SmokingUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Hartford HospitalYale UniversityNot yet recruitingMarijuana Use | Cannabis Use | Cannabis Intoxication
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNot yet recruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe
Clinical Trials on Contingency Management
-
VA Office of Research and DevelopmentRecruitingPTSD | Cannabis-Related DisorderUnited States
-
University of California, Los AngelesCompleted
-
Johns Hopkins UniversityJohns Hopkins Community PhysiciansWithdrawnSubstance-related DisorderUnited States
-
Douglas Mental Health University InstituteRecruitingPsychotic Disorders | Cognitive Dysfunction | Cannabis Dependence | Cannabis Use | Memory Impairment | Schizophrenia; Psychosis | Cannabis Use Disorder | NeuroimagingCanada
-
University of Colorado, DenverUniversity of Colorado, BoulderEnrolling by invitation
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed
-
UConn HealthNational Institute on Drug Abuse (NIDA)CompletedSubstance AbuseUnited States
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed